These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37750170)

  • 1. GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment.
    Tong Q; Li D; Yin Y; Cheng L; Ouyang S
    J Inflamm Res; 2023; 16():4153-4164. PubMed ID: 37750170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.
    Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W
    Front Immunol; 2022; 13():1048503. PubMed ID: 36582246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC.
    Fan H; Shi Y; Wang H; Li Y; Mei J; Xu J; Liu C
    Int J Gen Med; 2023; 16():1757-1769. PubMed ID: 37193249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
    Song Y; Sun Y; Sun T; Tang R
    Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of guanylate binding protein 5 in tumor immune microenvironment and predictive value of immunotherapy response.
    Li X; Song D; Su S; He X; Cao F; Yang C; Li K; Huang S; Li C; Wang C; Zhang A; Pang P; Zheng Y
    Front Genet; 2022; 13():984615. PubMed ID: 36246628
    [No Abstract]   [Full Text] [Related]  

  • 6. MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients.
    Wu L; Wang X; He X; Li Q; Hua Q; Liu R; Qiu Z
    Front Pharmacol; 2022; 13():868203. PubMed ID: 35431936
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
    Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
    Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-9-based immune risk score model helps to predict relapse in stage I-III small cell lung cancer.
    Chen P; Zhang L; Zhang W; Sun C; Wu C; He Y; Zhou C
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer.
    Tang Y; Hu Y; Niu Y; Sun L; Guo L
    Front Med (Lausanne); 2022; 9():834725. PubMed ID: 35252266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer.
    Li S; Qiu G; Wu J; Ying J; Deng H; Xie X; Lin X; Xie Z; Qin Y; Wang Y; Ma X; Brcic L; Provencio M; Chen Y; Zhou C; Liu M
    Transl Lung Cancer Res; 2022 Jul; 11(7):1380-1393. PubMed ID: 35958330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
    Korde R; Veluswamy R; Allaire JC; Barnes G
    Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer.
    Wei Y; Zheng L; Yang X; Luo Y; Yi C; Gou H
    Oncologist; 2023 Nov; 28(11):e1052-e1064. PubMed ID: 37399175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.
    Chen P; Wang H; Zhao L; Guo H; Zhang L; Zhang W; Sun C; Zhao S; Li W; Zhu J; Yu J; Wu C; He Y
    Front Oncol; 2021; 11():713853. PubMed ID: 34900670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
    He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H
    Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.